BIO vs MXCT
BIO: Bio-Rad provides essential tools and services for life science research and clinical diagnostics to help advance scientific discovery and improve patient outcomes. MXCT: MaxCyte provides proprietary non-viral cell engineering technology and gene-editing assessment services that empower developers to create next-generation cell and gene therapies.
Side-by-side fundamentals
| Metric | BIO | MXCT | Edge |
|---|---|---|---|
| Price as of 2026-10-21 close | $360.50 | $1.47 | |
| Market cap | $9.6B | $152M | |
| P/E as of 2026-10-21 | 43.91 (earnings are mostly non-operating: 85% of trailing pre-tax income, to 2026-06-30) | n/a | |
| Net margin FY2025, SEC XBRL | +29.4% | -135.1% | BIO higher |
| Gross margin FY2025, SEC XBRL | +51.9% | +81.2% | MXCT higher |
| Operating margin FY2025, SEC XBRL | +1.8% | -157.1% | BIO higher |
| ROE FY2025, SEC XBRL | +10.2% | -26.0% | BIO higher |
| ROA FY2025, SEC XBRL | +7.2% | -22.0% | BIO higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | 0.11 | n/a | |
| Revenue growth (YoY) FY2025, SEC XBRL | +0.7% | -14.5% | BIO higher |
| Revenue CAGR (3y) SEC XBRL | -2.7% | -9.3% | BIO higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.93 | 1.22 | |
| 1-year return as of 2026-10-21 close | +8.8% | -14.0% | BIO higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.